Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c

Ocular Therapeutix (NASDAQ: OCUL) reported Q4 EPS of ($0.42), $0.04 worse than the analyst estimate of ($0.38). Revenue for the quarter came in at $504 thousand versus the consensus estimate of $480 thousand.

For earnings history and earnings-related data on Ocular Therapeutix (OCUL) click here.

You May Also Be Interested In

• Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
• Visa deposits $405M into U.S. litigation escrow, adjusting stock rates
• Alcoa closes $2.6B debt offering to fund South32 asset acquisition